Summary
EudraCT Number: 2005-005452-41
Sponsor's Protocol Code Number: DPM-B-301
National Competent Authority: UK - MHRA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2006-04-10
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005452-41/GB/

A. Protocol Information
A.1 Member State Concerned: UK - MHRA
A.2 EudraCT number: 2005-005452-41
A.3 Full title of the trial: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic treatment of bronchiectasis.
A.4.1 Sponsor's protocol code number: DPM-B-301
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Pharmaxis UK Limited
B.1.3.4	Country: United Kingdom
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: DP Mannitol
D.3.4 Pharmaceutical form: Inhalation powder, hard capsule
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Inhalation use
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Information not present in EudraCT

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Inhalation powder, hard capsule
D.8.4 Route of administration of the placebo: Inhalation use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Bronchiectasis
MedDRA Classification
E.1.3 Condition being studied is a rare disease: Yes
E.2 Objective of the trial
E.2.1 Main objective of the trial: The study has two co-primary objectives: (1) to assess whether the effects of Bronchitol are beneficial to the quality of life in subjects with bronchiectasis using the St George’s Respiratory Questionnaire; and (2) to assess the impact of Bronchitol on mucus clearance (24 hour sputum sample)

E.2.2 Secondary objectives of the trial: Efficacy: To assess the impact of  Bronchitol on: (1) bronchiectasis symptoms (2) cough severity (3) exercise capacity (4) lung function, including gas transfer (5) antibiotic use (6) bronchial wall thickening and inflammation and (7) peripheral airway function 
Safety: To demonstrate the safety profile of Bronchitol (adverse events, haematology, biochemistry, sputum microbiology)

E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: (1) Evidence of  confirmed diagnosis of (non CF) bronchiectasis by HRCT (2) Age: 15 – 80 years inclusive (3) FEV1 50% - 80% predicted and ≥1.0L (4) Chronic cough (defined as persistently troublesome cough present on the majority of days in the 3 months prior to enrolment) (5) Chronic sputum production of >10 mL per day on the majority of days in the  3 months prior to study entry (6) Chronic chest congestion ( defined as chronic excessive accumulation of mucus in the lungs) (7) Ability to perform all the techniques necessary to measure lung function, and (8) Stable clinical condition at the time of, and for a period of 14 days prior to recruitment; defined as lack of: (a) change in techniques for sputum clearance (b) change in sputum production (volume, colour, consistency) (c) new or increased haemoptysis (d) increased cough (e) worsening dyspnoea (f) increased malaise, fatigue or lethargy (g) reduction in exercise tolerance (h) fever (g) increase in weight loss or anorexia (h) sinus pain/tenderness or change in sinus discharge (i) gastrointestinal symptoms such as diarrhoea, constipation, nausea, vomiting or (j) additional antibiotics (routine antibiotics permitted)
E.4 Principal exclusion criteria: (1) Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted (2) Bronchiectasis as a consequence of cystic fibrosis or focal endobronchial lesion (3) “Terminally ill” patients or those listed for transplantation (4) Use of hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry (5) Patients previously enrollment in a clinical trial using Bronchitol that was administered for more than a day (6) Significant episode of haemoptysis (>60 mL) in the previous 6 months (7) Exacerbation for which intravenous antibiotics were prescribed in the 4 weeks prior to study entry (8) Presence of airway hyperresponsiveness as defined by a positive Aridol challenge (9) Smoking history of >10 pack years or if more than 1 cigarette smoked per week within the previous 3 months (10) Likeliness of developing bronchoconstriction in response to Bronchitol in the opinion of the investigator (11) Myocardial Infarction in the three months prior to enrolment  (12) Cerebral vascular accident in the three months prior to enrolment (13) Major ocular surgery in the three months prior to enrolment (14) Major abdominal, chest or brain surgery in the three months prior to enrolment (15) Presence of cerebral, aortic or abdominal aneurysm (16) Active tuberculosis (17) Active malignancy including melanoma (other skin carcinomas and remissions exempted) (18) Females who are breast feeding or pregnant or plan to become pregnant during the study (19) At risk females unwilling to use appropriate contraception to prevent pregnancy during the study (20) Patients participating in another investigative drug study, parallel to, or within 4 weeks of study entry (21) Known intolerance to mannitol or β-agonists (22) Uncontrolled hypertension – systolic BP > 190 and or diastolic BP > 100 or (23) Patient has a condition or is in a situation which in the Investigator’s opinion may put the subject at significant risk, may confound results or may interfere significantly with participation in the study
E.5 End points
E.5.1 Primary end point(s): 1) Assessment of the effects of Bronchitol on quality of life as measured by a change in the score of the St George’s Respiratory Questionnaire; (2) Assessment of the impact of Bronchitol on mucus clearance (24 hour sputum sample)
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: Yes
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Yes
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Information not present in EudraCT
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: For children under 18 years of age
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 105
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 105
F.4.2.2 In the whole clinical trial: 354

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-05-15
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-05-26

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2008-06-05

